[Update of familial prostate cancer in Japan].
Explore the source record for details and available documents.
Genotype↗
Biomedical subjects
Yoshitatsu Fukabori
Publications and source records attributed to Yoshitatsu Fukabori.
MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
BACKGROUND: Magnetic resonance spectroscopy (MRS) is a new diagnostic tool which allows the detection of cellular metabolites. We assessed the usefulness of single- voxel MRS diagnosis for localization of prostate cancer. PATIENTS AND METHODS: The study population consisted of 10 patients with prostate cancer. We set I or 2 voxels at the peripheral zone (PZ) of the prostate where biopsy had confirmed adenocarcinoma. MRS provided metabolic information about citrate, creatine and choline levels. We calculated the ratio of these metabolites ([choline + creatine]/citrate) and judged areas where the metabolic ratio was greater than 0.86 as positive. RESULTS: Thirteen out of 19 voxels showed a cancer pattern which indicated a high choline peak and low citrate peak The accuracy, sensitivity and specificity of MRS diagnosis of tumor localization were 84.2%, 81.3% and 100%, respectively. CONCLUSION: MRS is useful for the diagnosis of prostate cancer localization.
Adenocarcinoma↗
Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.
BACKGROUND: To investigate the relationship between two common variants (Ser217 and Ala541) of the HPC2/ELAC2 gene and prostate cancer risk in a Japanese population, we performed a case-control study. MATERIALS AND METHODS: Cases and controls consisted of 81 prostate cancer patients with a family history and 106 controls. Ser217 and Ala541 polymorphisms were analyzed by the restriction fragment length polymorphism method. RESULTS: In controls, 94.5% and 100.0% had wild-type Ser217Ser and Ala541Ala genotypes, respectively. 5.7% of the controls had the Leu217 genotype. No Thr541 genotype was observed in the controls. 92.6% and 97.5% of the cases had the Ser217Ser and Ala541Ala genotypes. No significant differences were observed in the genotypic frequencies between controls and cases. We stratified prostate cancer cases according to the pathological grade (low- or high-grade) or the clinical stage (localized or metastatic). There was no statistical difference between the genotypic frequencies between the groups. CONCLUSION: The present study suggested that the common variants in the HPC2/ELAC2 gene play a limited role in the risk of prostate cancer in the Japanese population.
Adult↗